A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
NCT ID: NCT00399477
Last Updated: 2011-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2006-10-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Group 1 Patients using Azilect and no other therapy.
* Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea
NCT01268891
Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
NCT01479530
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
NCT01603069
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
NCT01765257
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
NCT01215227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rasagiline mesylate
rasagiline mesylate
Azilect®
Rasagiline mesylate plus adjunct therapy
Rasagiline mesylate with one of three adjunct therapies
Rasagiline mesylate plus Mirapex
Mirapex, Azilect®
Rasagiline mesylate with Levodopa
Azilect®, Levodopa
Rasagiline mesylate with Requip
Azilect®, Requip
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rasagiline mesylate
Azilect®
Rasagiline mesylate plus Mirapex
Mirapex, Azilect®
Rasagiline mesylate with Levodopa
Azilect®, Levodopa
Rasagiline mesylate with Requip
Azilect®, Requip
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Requiring therapy for PD symptom control
* Azilect monotherapy.
* Azilect as adjunct therapy..
Exclusion Criteria
2. Patients with pheochromocytoma
3. Concomitant MAO inhibitors or medications contraindicated for use with MAO inhibitors are not allowed.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Neuroscience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Teva Neuroscience
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MerriKay Oleen-Burkey, PhD
Role: STUDY_DIRECTOR
Teva Neuroscience, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TVP-1012/PM101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.